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The emergence of human immunodeficiency virus (HIV) drug-resistant mutations during antiretroviral therapy is explained by either the
preexistence of low-frequency-resistant strains before the start of therapy or by the selection of unsuppressed resistant strains during therapy.
We used pairwise and maximum likelihood analyses of the ratio of nonsynonymous to synonymous substitutions per site (dN/dS) to study the
extent of positive selection in the reverse transcriptase (RT) gene of HIV-1 from multiple data sets of drug-treated (117 sequences) and drug-
naive patients (270 sequences). In the pairwise analysis, evidence for positive selection (dN/dS > 1) was only found in drug-treated individuals
and in codons conferring drug resistance. By the maximum likelihood method, a positive selection at codons conferring drug resistance was
only observed in patients receiving therapy, and although positive selection was detected in drug-naive patients, this was always at codons
unrelated to drug resistance. We therefore document a striking difference in the process of allele fixation in drug resistance codons (RC)
between populations of HIV-1-infected individuals naive to treatment and those receiving therapy. Furthermore, although mutations
associated with drug resistance are sometimes found in drug-naive patients, we suggest that these are fixed because of linkage to sites
experiencing immune escape. Finally, we show that compensatory changes are likely to be important in the development of HIV drug
resistance by counter-acting the deleterious effects normally associated with drug resistance mutations.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV-1; Positive selection; Antiretroviral resistance; Compensatory mutations; Drug-naive individuals; Population genetics
Introduction mutation, replication, and recombination, and immenseThe reverse transcriptase (RT) enzyme of the human
immunodeficiency virus type 1 (HIV-1) converts viral
genomic single-stranded RNA into double-stranded DNA.
This is an essential step in the viral life cycle such that the
RT has been a target of antiretroviral therapy. Even when
antiretroviral drugs drastically reduce HIV-1 replication
and viral RNA is undetectable in plasma, viral suppression
is not complete (Chun et al., 1997; Fleury et al., 2000;
Lewin et al., 1999). Because HIV-1 has high rates of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: pzanotto@usp.br (P.M. de A. Zanotto).population sizes (Bebenek et al., 1989; Jung et al., 2002;
Mansky and Temin, 1995), intra-host viral populations
may show considerable genetic diversity. In particular,
the high error rate of the RT, estimated at approximately
104 mutations per site, per replication (Bebenek et al.,
1989; Mansky and Temin, 1995), means that in a viral
genome of length 10 kb, approximately one mutation is
introduced on average at each replication cycle during the
synthesis of viral DNA. Because many of these mutations
are deleterious to the virus, the rate at which mutations are
fixed (substituted) in the population is approximately 2.3
105 substitutions per site, per replication (Perelson et al.,
1996).
At any time, a large fraction of an intra-host HIV
population represents the most adapted viral genome under
the current selective pressures, such as those imposed by the
human immune response or by drug therapy. Nevertheless,
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mutational variants, including those that confer drug resis-
tance even though antiviral therapy has not been instigated
(Blower et al., 2000; Gomez-Cano et al., 1998; Larder et al.,
1989; Moore et al., 1991; Na´jera et al., 1994; Ribeiro and
Bonhoeffer, 2000; Richman et al., 1991). In many cases,
drug resistance mutations are likely to be naturally delete-
rious to HIV in the absence of drug, but their fitness benefit
during therapy is such that they are eventually fixed in the
population (Larder et al., 1991; Na´jera et al., 1994). There-
fore, the presence of normally deleterious changes in a HIV
population could reflect the transient presence of alleles that
will eventually be removed by purifying selection, the
action of genetic drift fixing such mutations when popula-
tion sizes are small (Frost et al., 2001; Holmes and Zanotto,
1998; Leigh Brown, 1997; Leigh Brown and Richman,
1997; Rouzine and Coffin, 1999a, 1999b), or the occurrence
of compensatory changes that raise the fitness of viruses
carrying normally deleterious drug resistance alleles to
values near the wild type (Ribeiro and Bonhoeffer, 2000;
Rouzine and Coffin, 1999a). However, despite the large
body of work considering the dynamics of allele substitution
during antiviral therapy, the respective roles of natural
selection, genetic drift, and compensatory changes are
unclear although central to predicting the future spread of
drug resistance mutations. Furthermore, it is uncertain
whether those drug resistance mutations that sometimes
appear in drug-naive patients are subject to the same
evolutionary processes that determine their spread in drug-
treated individuals.
Herein, we describe the selection pressures acting on the
RT gene from many patients who are either drug-naive or
drug-treated by comparing the ratio of nonsynonymous (dN)
to synonymous (dS) substitutions per site, with a dN/dS ratio
>1 indicating a positive selection. To make our analyses of
selection pressures as rigorous as possible, we employ both
the pairwise method of Kumar et al. (2001) and a codon-
based maximum likelihood method that incorporates gene-
alogical information from the sequences under consideration
(Yang et al., 2000). We show that evolutionary processes in
the RT differ considerably between drug-naive and drug-
treated patients.Table 1
Pairwise analysis of dN and dS in subgroups of drug resistance codons (RC) and
drug-naive individuals
Subgroups of codons
RC (32 codons)
dN (SE) dS (SE) dN/dS (t test)
Average values in 15 drug-naive data sets
1.450 (0.442) 2.656 (0.600) 0.570a (t = 1.618, P < 0.05)
Average values in seven drug-treated data sets
4.302 (1.438) 2.32 (0.738) 1.948 (t = 1.227, P > 0.2)
a Denotes dN/dS significantly different from 1 at the 95% confidence interval with
freedom.Results
HIV subtyping
To establish the HIV-1 subtype of the Sa˜o Paulo (SP)
patients, we estimated a phylogeny of their RT sequences
along with a panel of subtype reference sequences from the
Los Alamos HIV database (tree not shown; available from
the authors upon request). Using this analysis, we found that
73 represented subtype B (82.5%) and 12 represented sub-
type F (14.1%).
Drug resistance mutations in drug-naive patients
Initially, we screened for amino acid changes associated
with resistance to antiretroviral drugs in drug-naive individ-
uals. This required the analysis of two data sets—Sa˜o Paulo
(SP) and Boden et al. (1999). Several mutations known to
confer drug-resistance were observed in the SP data set
(Table 2). Specifically, 10 of the 85 RT sequences from the
SP data set harbored mutations associated with resistance to
non-nucleoside reverse transcriptase inhibitors (NNRTIs),
and one patient contained a substitution (M184I) associated
with resistance to nucleoside reverse transcriptase inhibitors
(NRTI). This latter mutation is commonly seen after 2 weeks
of monotherapy with lamivudine (3TC) and drastically re-
duces the processivity of theRT (Back et al., 1996). Converse-
ly, in the Boden et al. data set, drug resistance mutations were
more frequent (26/80) and equally represented both classes
of drugs. As well as mutations associated with drug resis-
tance, both data sets of drug-naive patients showed a variety
of other variable codons, most notably positions 211 and 214.
Pairwise analysis of selection pressures
The pairwise analysis of dN/dS provided some prelimi-
nary indication of differences in selection pressure between
drug-treated and drug-naive patients as mean dN/dS was
higher in 117 drug-treated individuals (1.061) than in 270
drug-naive individuals (0.564), although in both cases the
null hypothesis of neutral evolution (dN/dS = 1) could not be
rejected (Table 1).other codons (OC) from seven data sets of drug-treated and 15 data sets of
OC (194 codons)
dN (SE) dS (SE) dN/dS (t test)
9.983 (1.750) 15.826 (1.628) 0.627a (t = 2.445, P < 0.02)
8.287 (1.788) 12.583 (1.884) 0.698a (t = 1.654, P < 0.05)
a t test, where t ¼ ðdS  dNÞ= ﬃp ½SEðd2SÞ þ SEðd2NÞ and infinite degrees of
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patients was associated with positive selection at codons
related to antiretroviral resistance, we subdivided the RT
gene into: (i) 32 drug-resistance codons (RC) and (ii) the
other 194 codons (OC) that remained after exclusion of the
drug-related codons. The average values of dN/dS for RC
and OC subgroups from both drug-treated and drug-naiveTable 2
Positively selected codons in the RT gene in drug-naive individuals identified us
Data set
(no. of sequences)
Drug-resistance codons founda
Drug-nave individuals
Sa˜o Paulo B (73) T69N, A98G, K101E, K103R, V108I, M184I
Sa˜o Paulo F (12) None
Sa˜o Paulo-Res (10) T69N, A98G, K101E, K103R, V108I, M184I
Sa˜o Paulo-Poly (12) T69N
Los Alamos-B (21) K103R
Los Alamos-C (8) V179D
Stanford 1994 (20) K103R
Stanford 1995 (12) K103R, V179D
Stanford 1997 (10) None
Stanford 1998 (16) None
Stanford combined (58)e K103R, V179D
Boden 1999
combined (80)f
M41L, D67N, T69D, K70R, V75M/L, K103N,
V179D/E, M184V, L210W, T215F
Boden-Res (25) M41L, D67N, T69D, K70R, V75M/L, K103N,
V179D/E, M184V, L210W, T215F
Boden-Poly (30) None
Brindero 1999 (18) M41L, D67N, K70R, T215F, K219Q
Drug-treated individuals
Loussert and Ajaka (9) M41L, D67N, K70R, W88Sg, A98G, V106I,
Y181C, M184V, L210W, T215Y
Hooker and Smith (7) M41L, V75I, A98S, K103N, Q151M, M184V,
L210W, T215Y
Eron et al. (21) M41L, D67N, K70R, K101E, M184V, G190A,
L210W, T215F/Y
Gunthard et al. (24) M41L, D67N, M184V, L210W, T215Y, K219Q
Schmit et al. (44) M41L, D67N, T69D/S, K70R, L74V, V75I,
A98G, Y115F, E138A/G, Q151M, M184V/I,
L210W, T215Y/F, K219E
Winter et al. (5) M41L, K70R, T69A/S, Y181C, L210W, T215Y
Stanford 1998 (7) M41L, D67N, L74I, M184V, L210W, T215Y
All-treated combined
(n = 117)
a Drug-resistance codons are those listed at the Los Alamos HIV-1 drug resistan
underlined.
b The proportion of sites with dN/dS V 0.25 was estimated using model M8 of C
c Only positively selected codons with statistical support of P > 0.99 under mode
d The number of different HLA-haplotypes that recognize epitopes where the cod
e ‘‘Stanford combined’’ includes all 58 sequences from 1994, 1995, 1997, and 19
f ‘‘Boden combined’’ includes all 80 sequences from Boden et al. (1999).
g This mutation is associated with resistance to pyrophosphate analogues.data sets are shown in Table 1. These results are striking in
that dN/dS was consistently >1 for the RC codons (mean =
1.948) of the drug-treated patients and consistently <1 for
the OC codons (mean = 0.698), although the null hypothesis
of neutral evolution of the RC codons again could not be
rejected (P > 0.2). Despite a lack of statistical significance,
perhaps explained by the relatively small sample sizes, theseing a maximum likelihood method
Proportion of
codons with
dN/dS V 0.25
b
Proportion of
codons with
dN/dS > 1
c
Positively selected codonsc
(no. of haplotypes)d
0.826 0.040 122 (3), 162 (9) 177 (3),
200 (1), 211 (6)
0.917 0.033 None
0.962 0.038 None
0.881 0 None
0.810 0 None
0.908 0.092 39 (3), 43 (5), 135 (4), 162 (9),
166 (10), 207 (5)
0.918 0.083 200 (1), 211 (6)
0.914 0.086 125 (3)
0.932 0.068 35 (2), 122 (3), 123 (3), 135 (4),
207 (5), 211 (6)
0.896 0.104 35 (2), 122 (3), 123 (3), 125 (3),
162 (9), 178 (3), 200 (1), 211 (6)
0.856 0.064 35 (2), 122 (3), 123 (3), 135 (4),
177 (3), 200 (1), 207 (5),
211 (6), 214 (1)
0.864 0.062 25 (2), 66 (0), 113 (2), 125 (3),
152 (1), 197 (1), 201 (5), 205 (5)
0.762 0.004 None
0.849 0.047 25 (2), 73 (1), 113 (2), 125 (3),
152 (1), 169 (1), 197 (1), 201 (5)
0.836 0.052 None
0.809 0.019 None
0.809 0.191 151 (1), 202 (5), 204 (5), 215 (1)
0.900 0.100 70 (0), 83 (0), 122 (3), 177 (3)
0.748 0.023 None
0.715 0.116 35 (2), 67 (0), 69 (0), 70 (0),
118 (3), 151 (1), 207 (5), 210 (6),
211 (6), 214 (1), 215 (1)
0.906 0.093 68 (0), 122 (3)
0.787 0 None
0.948 0.051 35 (2), 41 (5), 67 (0), 69 (0), 70 (0),
118 (3), 122 (3), 123 (3), 135 (4),
151 (1), 184 (4), 207 (5), 210 (6),
215 (1)
ce database. Positively selected codons associated with drug resistance are
ODEML (Yang et al., 2000).
l M8 are listed.
on is located.
98.
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directed against drug resistance codons in individuals re-
ceiving antiviral therapy. Conversely, in drug-naive individ-
uals, mean dN/dS was significantly <1 for both RC (0.570,
P < 0.05) and OC (0.627, P < 0.02) codons, revealing the
action of purifying selection.
Maximum likelihood analysis of selection pressures
To obtain a more refined measure of the codon-specific
selection pressures acting on the RT sequences, we per-
formed a maximum likelihood analysis of dN/dS in both
the drug-naive and drug-treated patient data sets (Table 2).
The results for 15 drug-naive groups indicated that al-
though significant positive selection (P < 0.001 for both
M3 and M8) was detectable at a variety of codons, none
were associated with drug resistance. The lack of drug
associated positive selection is particularly notable given
that drug resistance substitutions for both NRTIs and
NNRTIs drugs were found in most drug-naive data sets
(Table 2). Moreover, with the exception of codon 66, all
these selected codons were located within CTL epitopes
(Table 2 and Fig. 1).
A very different picture of selection pressures was
observed in those patients who have received drug therapy.
Positive selection was detected at various codons in four of
the seven drug-treated data sets (Table 2). Most notably, a
variety of these codons are associated with the development
of drug resistance (Table 2 underlined). However, not all
mutations known to confer drug resistance were positively
selected, and many of the selected codons were unrelated to
antiviral resistance. Because most of the drug-treated data
sets had a few sequences, we repeated the analysis on a
combined data set of the 117 sequences from the drug-
treated patients (‘‘All-Treated Combined’’). This identified
additional codons under positive selection at sites 41, 123,
135, 184, 207, and 210 (Table 2). Although the functionalFig. 1. Overall mean dN/dS ratios in RT codons estimated under model M8 in CO
drug-treated patients. ‘‘All-Naive’’ = mean dN/dS in all codons of the 15 data sets o
of the seven data sets of drug-treated patients. ‘‘RC-Naive’’ = mean dN/dS in druconsequences of positive selection at codons not related to
drug resistance are unclear, the rest fell into known CTL or
T-helper epitopes with the exception of codon 83 (Fig. 2)
(Korber et al., 2001). Codon 83 was under positive selection
in a drug-treated data set (‘‘Eron et al’’ Table 2) and was
neither associated with drug resistance nor inside CTL
epitopes, thus suggesting that it may have a compensatory
function to recover fitness of drug-resistant viruses.
Our analysis also revealed a strong association between
positive selection and the presence of CTL epitopes. Indeed,
positively selected codons in drug-naive patients were
significantly more likely to fall into regions containing
CTL epitopes than other genomic regions (v2 = 5.5217,
P < 0.0189). In contrast, there was no difference in the
location of positively selected codons in drug-treated
patients with respect to the location of CTL epitopes (v2 =
0.0507, P < 0.8198) (Table 3). Some precise examples of
the links between drug resistance and CTL escape were also
apparent. For example, the drug-resistance mutation at
position 210 and the polymorphisms at positions 201,
205, 207, and 211 are all located within the HLA-B60-
CTL (B*4001/B60) restricted epitope (Korber et al., 2001;
McAdam and Gotch, 1999; Wainberg, 1999). Likewise,
positions 35, 122, 123, 135, 177, and 211, which were
selected in both drug-treated and drug-naive individuals, are
in regions with high density of epitopes (Fig. 1). Therefore,
perhaps most of the positively selected codons not related
with drug resistance function as targets to the immune
system, as suggested in recent large-scale studies (Moore
et al., 2002; Yusim et al., 2002).
In addition, we found evidence for linkage between
polymorphic codons (under positive selection) and drug-
related substitutions (not under positive selection) in both
drug-naive and drug-treated patients. For example, codon
177 (under positive selection in drug-naive patients) and the
drug-related substitution at position 179 (not under positive
selection) are both located within the HLA-B*3501-CTLDEML. ‘‘All-Treated’’ = mean dN/dS in all codons of the seven data sets of
f drug-naive patients. ‘‘RC-Treated’’ = mean dN/dS in drug-resistance codons
g-resistance codons of the 15 data sets of drug-treated patients.
Fig. 2. Association between positively selected codons and CTL epitopes in the RT gene of HIV-1. The RT sequence corresponds to sites 1–219 of the HXB2
strain. Dots above particular residues denote the positively selected codons in drug-treated patients, while triangles below residues represent positively selected
codons in drug-naive patients. All drug-resistance codons are underlined and CTL epitopes experimentally determined according to a panel of MHC-I
haplotypes are highlighted. Figure modified from HIV Molecular Immunology data base (Korber et al., 2001).
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patients, the drug-associated mutations at codon 179 (not
under positive selection) and 184 (under positive selection)
are located within the HLA-B51-CTL restricted epitope (RT
174–184) (Fig. 1).
Despite widespread evidence for positive selection, the
dominant evolutionary processes in the RT from both
patient groups were purifying selection; in most data sets,
irrespective of treatment, the majority of codons (71.5–
96.2%) have dN/dS values V0.25, indicative of fairly strong
structural–functional constraints (Table 2). Similarly, mean
dN/dS values (estimated under the maximum likelihood
method) showed a pattern of constraint, although the resis-
tance codons in drug-treated patients (‘‘RC-Treated’’) have
elevated values of dN/dS (Fig. 2).
Positive selection before and after monotherapy with
didanosine (ddI)
To better understand the evolutionary effects of antire-
troviral therapy, we analyzed selection pressures in 49 RTTable 3
Association between positively selected sites and CTL epitopesa
Drug-naive Positively selected sites
(triangles in Fig. 2)
Other codons
Inside-epitope 22 144
Outside-epitope 1 52
v2 = 5.5217, df = 1, P < 0.0189
Drug-treated Positively selected sites
(dots in Fig. 2)
Other codons
Inside-epitope 14 152
Outside-epitope 5 48
v2 = 0.0507, df = 1, P < 0.8198
a This test is based on the location of CTL epitopes presented in Fig. 2 and
compares the significance of finding positive selected sites inside and
outside CTL epitopes. The test is only significant in drug-naive patients.sequences of the same group of patients before and after
(1 year) monotherapy with didanosine (ddI). The maximum
likelihood provided no significant evidence for positive
selection at any codon, before or after therapy. Nevertheless,
before therapy, all patients had leucine (L) at codon 74 while
during therapy 16 of 49 patients acquired valine (V) at this
site. The mutation 74V is directly associated with ddI
resistance.
Phylogenetic analysis of mutations in drug-naive and
drug-treated populations
The presence of drug resistance mutations in drug-
naive patients is intriguing, especially as we found no
evidence that they have been subjected to positive selec-
tion. To investigate their evolutionary history in more
detail, we conducted a phylogenetic analysis of the RT
sequences from the drug-naive SP and Boden et al. data
sets.
The topology of the SP tree is notable in that the
sequences containing drug-resistant mutations or that are
polymorphic at resistant codons are usually evenly dis-
tributed among the terminal branches (Fig. 3). This
suggests that most of these mutations have occurred
independently and have not been transmitted for sustained
periods of time. However, a few exceptions were found in
sequences that share either drug-resistance mutations or
polymorphisms. In these cases, it is important to deter-
mine if the resistance mutations were transmitted together
or have converged within individual hosts. In the case of
sequences SP72 and SP80, the former has drug resistance
mutations at position M184I and latter at position G190E,
and they share the same polymorphisms (M41I and T69P)
at drug-related codons, although none of these mutations
were under positive selection. However, as SP72 and
SP80 do not cluster together, these mutations were most
likely acquired through convergent evolution, a theory
supported by the observation that they are both charac-
Fig. 3. Maximum likelihood phylogenetic trees for HIV-1 RT genes of drug-naive individuals from the (A) Sa˜o Paulo and (B) Boden et al. (1999) data sets.
Lineages bearing resistance mutations are shown by closed circles, polymorphisms at drug resistance codons by shaded circles, and wild-type mutations by
white circles, using HXB2 as a reference strain. Sister lineages having the same drug resistance mutations (denoted *) and sister lineages having the same
polymorphisms in drug-resistance codons (denoted §) are also indicated. To indicate the reliability of our phylogenetic reconstructions, the values from 500
bootstrap replicates done with the neighbor-joining method in PAUP* and the percent of the time a node was supported by the quartet-puzzling method (TREE-
PUZZLE, http://www.tree-puzzle.de/) (Strimmer and von Haeseler, 1996) are shown, respectively, near the branches for important nodes only. All trees are
unrooted with horizontal branch lengths drawn to scale.
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SP63 share the drug-resistance mutation A98G and the
polymorphism at R211K, the latter being selected in
several data sets, and group together on the tree. The
genetic distance between these two sequences (d = 0.034)
implies that they diverged at least 5 years before sampling
(assuming a substitution rate of 2.3 	 105 substitutions
per site, per year), so that this mutation has persisted in
the population for at least 1403 viral generations in the
absence of continuous drug pressure (under an average
viral generation time of 2.6 days). Likewise, sequences
M5 and N3 from the Boden data set share the drug-
resistance mutation V75L (d = 0.057) and diverged at
least 9 years before sampling, while sequences D10 and
S2 share the V179I polymorphism (d = 0.019) and
diverged at least 3 years before sampling. If these drug-
related mutations were indeed in the common ancestor of
each sequence pair, then their persistence in the popula-
tion despite their deleterious effects in the absence of drug
suggests that compensatory mutations may be required to
recover fitness.Discussion
Natural selection and drug resistance
There is compelling evidence that the positive selection
of advantageous mutations is a key process in HIV
evolution, both for drug resistance (Crandall et al., 1999;
Frost et al., 2001) and immune escape (Ross and Rodrigo,
2002; Williamson, 2003; Yang et al., 2000; Zanotto et al.,
1999). Despite this, some authors have suggested that
allele fixation in HIV populations is often a stochastic
process, with genetic drift the dominant force (Frost et al.,
2000; Leigh Brown and Richman, 1997). This is due to a
complex interaction of factors, including small and fluc-
tuating effective population sizes, changes in cellular
conditions (target cells), nonuniform distribution of
viruses, variation in host immune responses (namely levels
of CD8+and CD4+), differing combinations of antiretrovi-
ral drugs, and co-infection with multiple strains (Ribeiro
and Bonhoeffer, 2000; Rouzine and Coffin, 1999a,
1999b).
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whatever their fitness, are subject to drift when they first
appear and are at low frequency in viral populations, our
study strongly supports the idea that the evolution of drug
resistance in HIV is a selectively driven process. In partic-
ular, the only evidence for positive selection at known
resistance codons was found in patients undergoing antiviral
therapy. A similar result was recently obtained in a study of
RT sequences from African drug-naive individuals infected
with subtype C viruses (Gordon et al., 2003). Consequently,
we conclude that drug resistance mutations in drug-naive
and drug-treated patients are subject to different evolution-
ary processes, with positive selection predominant in the
latter.
Of particular note was our observation that drug resis-
tance mutations in drug-naive patients have not been fixed
as a result of their individual fitness advantage. Moreover,
many of these mutations appear to be deleterious for the
virus in the absence of drug pressure. For example, M184I
and G190E (found in sequences SP72 and SP80) are known
to cause a drastic loss of viral fitness in the absence of drug
(Back et al., 1996; Boyer et al., 1998; Fan et al., 1996). In
particular, M184I is located at the YMDD catalytic motif of
the polymerase active site of RT and confers high level of
resistance to 3TC (lamivudine). However, viruses with this
mutation have lower fitness relative to wild-type viruses and
are frequently replaced by a fitter 3TC-resistant mutant
(M184V). Likewise, G190E causes a drastic reduction in
catalytic and RNaseH activities, and polymorphisms at
codons 74 and 75 have been shown to compensate for the
effects of G190E on RT processivity (Boyer et al., 1998).
The inviability of these mutants in the absence of drug
implies that compensatory mutations rescue the fitness of
the mutant to near that of wild type. In this context, it is
noteworthy that the majority of drug-resistance codons are
invariant in most of the HIV subtype sequences in the Los
Alamos database. This implies that these sites are highly
conserved because of structural–functional constraints so
that any mutations at these sites will normally be deleteri-
ous. This is confirmed by our observation that most RT
codons are under strong purifying selection.
How then to explain the long-term persistence of delete-
rious drug-related mutations in the absence of drug? In some
cases, it is possible that we have by chance sampled
deleterious mutations shortly before their selective removal
from the population. Although this may be true for a subset
of the resistance mutations, particularly those that fall on the
terminal branches of the phylogenetic tree, suggesting that
they appeared recently, it is unlikely to explain every
occurrence of a drug resistance mutation in a drug-naive
patient. Another possibility is that their spread is entirely
due to the random sampling associated with genetic drift.
However, we consider this scenario to be unlikely because
of the extended time it takes genetic drift to fix neutral
mutations; if we conservatively assume an effective popu-
lation size (Ne) of 10
4, genetic drift would take an averageof 42 years (i.e., 2Ne viral generations) to fix these muta-
tions. Consequently, even though these drug resistance
mutations may not have achieved complete fixation, it is
difficult to imagine how their presence can be entirely due to
random sampling. As such, their prolonged presence in the
viral population again suggests that associated mutations
play a compensatory role to recover viral fitness. The
importance of compensatory mutations has previously been
observed in relation to CTL escape in HIV. In this case, a
key CTL escape mutation (R264K) in p17 gag from HLA-
B27+ patients could only spread to fixation if accompanied
by one or two nearby compensatory mutations that restored
the function of the viral capsid (Kelleher et al., 2001).
If drug-resistant mutations in drug-naive patients gener-
ally have low individual fitness such that compensatory
mutations are essential, then their presence in the population
is most likely due to linkage with mutations and that have
been selected because they confer immune escape. Indeed,
most resistance codons fall within known CTL epitopes
(Korber et al., 2001), and in the drug-naive data sets,
significant evidence for positive selection was always found
in non-resistance codons, many of which reside in CTL
epitopes. This idea is also supported by the presence of
positively selected codons and drug-related mutations with-
in the same CTL epitopes. In these circumstances, the
strength of both linkage and selection pressure for CTL
escape would need to be strong enough to counteract the
affect of recombination, which may be extremely frequent
within HIV populations (Jung et al., 2002). This is clearly a
model that needs to be explored further. Indeed, to fully
understand the importance of immune selection and com-
pensatory changes in the evolution of drug resistance
mutations in drug-naive patients will require longitudinal
studies of the substitution process of mutant HIV alleles.
Antiretroviral therapy and HIV evolution at the population
level
Because HIV replication may not be completely sup-
pressed under antiretroviral therapy, even with good adher-
ence (Chun et al., 1997; Fleury et al., 2000), it has been
proposed that drug-resistant strains will attain high frequen-
cies in infected populations, as has been observed (Angar-
ano et al., 1994; Boden et al., 1999; Conlon et al., 1994;
Perrin et al., 1994; Salomon et al., 2000; Yerly et al., 1999).
Our observation of an increase in frequency of L74V in the
presence of ddI may be such a case of transmission of drug-
resistant strains at the population level. Conversely, the
observation that most amino acid sites associated with
resistance are conserved in the absence of drug therapy
suggests that they are generally deleterious and may require
compensatory changes to recover fitness (Richman et al.,
1991). Therefore, it can be argued that in the absence of
compensatory changes and drug pressure, most resistant
strains are not able to spread far in drug-naive individuals
unless they are by chance linked to immune system escape
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weak force at the population level in HIV, so that mutants
with high fitness within hosts may not attain high frequen-
cies. The relative weakness of selection as a determinant of
inter-host evolution is due to several factors; that rates of
partner exchange vary enormously between hosts so that
genetic drift dominates substitution dynamics, that the large
population bottleneck at transmission counters the inheri-
tance of favorable mutations, and that many advantageous
mutations, such as those involved in drug resistance or CTL
escape, arise relatively late during the life history of an
individual HIV infection and so are unlikely to be transmit-
ted to new hosts (Rambaut et al., 2004). Consequently,
mutations that are selectively favored within individuals
may only have limited reproductive success at the popula-
tion level.
In sum, we have shown that the evolution of drug-
resistant mutations differs dramatically between drug-trea-
ted and drug-naive populations, with the former dominated
by positive selection and the latter most likely spreading in
linkage with immune-selected changes. We also suggest that
because many HIV drug resistance mutations are naturally
deleterious, compensatory changes are critical to under-
standing their evolutionary dynamics.Methods
Samples
The patients enrolled in this study were monitored at the
Infectious Diseases Discipline (DIPA) of the Federal Uni-
versity of Sa˜o Paulo (UNIFESP) and at the AIDS Clinics of
the Department/Division of Infectious Diseases, School of
Medicine of the University of Sa˜o Paulo. Patients were
classified as ‘‘drug-naive’’ and selected according to the
following criteria: (i) HIV-1 positive (as determined by
ELISA and Western blotting), (ii) no previous treatment
with any antiretroviral drug, and (iii) at least 18 years of age.
Patients under any other kind of drug regimen were also
excluded from the study. Based on the clinical records (data
not shown), most of the individuals enrolled in this study
were infected through heterosexual contact and were asymp-
tomatic when sampled.
Viral isolation and sequencing
DNA was extracted from whole blood frozen samples
using QIAamp viral DNA kit (Qiagen Inc., Chatsworth,
CA) according to the manufacture’s instructions. PCR
reactions were made using a nested approach to generate
fragments of the RT gene of HIV-1. The following primers
were used in the amplifications. For the first round of
amplification, we used the Kozal-1 primer (Kozal et al.,
1996), 5V-CAG AGC CAA CAG CCC CAC CA-3V (nucle-
otide position of HIV-1 HXB2: 2146–2165); and Kozal-2,5V-TTT CCC CAC TAA CTT CTG TAT GTC ATT GAC A-
3V (3307–3337). For the second round, we used both the
Frenkel-1 primer (Frenkel et al., 1995), 5V-GTT GAC TCA
GAT TGG TTG CAC-3V (2518–2538); and Frenkel-2, 5V-
GTA TGT CAT TGA CAG TCC AGC-3V(3300–3320).
PCR reactions had a final volume of 50 l, containing 10
mMTris–HCl, pH 8.0, 50 mMKCl, 3.5 mMMgCl2, 0.2 mM
of each dNTP 0.2 M of each primer and 2.5 U of Taq DNA
polymerase (Gibco BRL). First and second round reactions
were incubated at 94 jC for 10 min, then 30 cycles of 94 jC
for 30 s; 58 jC for 45 s; 72 jC for 1–2 min, and a final
extension of 72 jC for 10 min. All reactions were performed
on a Perkin-Elmer thermal cycler (model GeneAmp 2400).
Second round PCR products were inspected by electropho-
resis on 1.5% agarose gels stained with ethidium bromide
using 0.5	 TBE buffer.
Bulk PCR amplicons (second round) were purified with
the QIAquick PCR purification kit (Qiagen Inc.) and direct-
ly sequenced. Cycle sequencing was done on both strands
with the same primers used in the second round of the PCR
using the Big Dye Terminator Cycle Sequencing Ready
Reaction kit (Perkin-Elmer Applied Biosystems) and
AmpliTaq DNA polymerase, according with the manufac-
turers instructions. Electrophoresis of the sequencing react-
ions was done with an automated capillary sequencer (ABI
PRISM 310 Perkin-Elmer Applied Biosystems). Nucleic
acid sequences were edited utilizing Sequence Navigator
software (Applied Biosystems). The electropherograms of
both strands were aligned and a consensus sequence was
obtained. Consensus sequences were translated and edited
manually, resulting in a data set containing 85 nucleic acid
sequences of RT gene with length of 678 bp (226 codons).
These sequences have been deposited on GenBank (acces-
sion numbers AF480743–AF480832).
Drug-naive and drug-treated data sets
For comparative purposes, sequences of the RT gene
from other data sets of both drug-naive or drug-treated HIV-
infected patients were obtained from the Los Alamos HIV
data base (http://hiv-web.lanl.gov), the Stanford HIV data
base (http://hivdb.stanford.edu/hiv/), GenBank, or directly
from the authors of previous studies. These included 18
sequences from Rio de Janeiro (Brindeiro et al., 1999), 80
sequences from United States (Boden et al., 1999), and a
further 58 taken from the Stanford and Los Alamos data-
bases. This last data set included representatives from other
subtypes to allow HIV subtype assignment. Overall, we
collected 15 data sets of drug-naive patients and seven data
sets of drug-treated patients, and where possible the sequen-
ces were analyzed according to the year of sampling. As
shown in Table 2, the data sets were also designated
according to their component subtypes when necessary
(e.g., SP-F, Los Alamos C). Finally, we analyzed 49
sequences sampled from patients before and after (1 year)
therapy with didanosine (ddI).
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Sequences were aligned using the ClustalW package
(Thompson et al., 1994) and the SE-AL program (Rambaut,
1999). All insertions, deletions, and stop codons were
removed before analysis. The subtype classification of the
Sa˜o Paulo RT sequences was established by comparing our
sequences to those from the HIV subtype references through
maximum likelihood (ML) phylogenetic analysis using the
PAUP* package (Swofford, 2002) (all parameter values
available from the authors upon request). To estimate the
divergence time (T) between any two HIV sequences, we
assumed a viral generation time ( g) of 2.6 days and a
nucleotide substitution rate (r) of 2.3 	 105 per generation
(Perelson et al., 1996). Using corrected pairwise distances
(d) between sequences, we can then estimate T by the
relation T = d/2r.
For the maximum likelihood analysis of selection pres-
sures (see below), phylogenetic trees are required for each
data set. We first determined the most appropriate model of
nucleotide substitution for each data set using the program
Modeltest v3.06 (Posada and Crandall, 1998). A starting
tree under this model was then obtained through the quartet-
puzzling method available in PAUP*, and these trees were
then swapped using the nearest-neighbor interchange search
algorithm until the tree of highest likelihood was obtained.
Analysis of selection pressures
We used both pairwise and codon-specific methods to
estimate selection pressures. Initially, we compiled data sets
of all the RT sequences from drug-naive patients (n = 270)
and drug-treated patients (n = 117) and determined the mean
dN/dS in these two groups using the pairwise method of
Kumar et al. (2001) as implemented in the MEGA v2.1
package. Next, we estimated dN/dS separately for each of the
15 data sets of drug-naive patients and seven data sets of
drug-treated patients. Rather than estimating mean dN/dS
values across the whole sequence, we analyzed separately
codons associated with drug resistance (denoted RC) and
other codons not associated with drug resistance (denoted
OC). The RC subgroup was composed of the following 32
codons, according to the Stanford HIV database: M41, E44,
K65, D67, T69, K70, L74, V75, L92, A98, L100, K101,
K103, V106, V108, Y115, V118, E138, T139, G141, Q151,
Q161, V179, Y181, M184, Y187, V188, G190, H208,
L210, T215, and K219. We also used a maximum likelihood
method to determine codon-specific selection pressures, as
implemented in the CODEML program from the PAML v.
3.14 package (Yang et al., 2000). This compares the fit to
the data of various models of codon evolution, which differ
in the distribution of dN/dS among sites and take into
account the phylogenetic relationships of the sequences.
Model 0 (M0) assumes a single dN/dS for all sites in the
alignment and hence is the simplest model specified. The
‘‘neutral’’ model (M1) allows different proportions of con-served sites (dN/dS = 0) and neutral sites (dN/dS = 1), both
estimated from the data. M2 adds an additional class of sites
with its dN/dS ratio (which can be >1) estimated from the
data. M3 also allows positive selection by incorporating
three categories of codon sites with the dN/dS value at each
estimated from the data. M7 specifies 10 categories of dN/
dS, none of which may be <1, so the model only allows
neutral evolution. Finally, M8 incorporates an extra (11th)
class of sites to M7 that can take on any value of dN/dS,
including those supporting positive selection. Nested mod-
els can be compared using a standard likelihood ratio test
(LRT). Significant evidence for positive selection is provid-
ed if M2, or more normally M3, significantly rejects M0 and
M1, if M8 significantly rejects M7, and if the favored
models contain a class of codons where dN/dS > 1. If
positive selection is detected, individual codons subject to
positive selection can be determined using the Bayesian
methods available in CODEML.Acknowledgments
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